Latest News
Category: Events
Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA...
Read more
Telix today announces that final results from the ZIRDOSE-CP Phase 1 study of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma (ccRCC) have been published...
Read more
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA...
Read more
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco,...
Read more
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...
Read more
Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week....
Read more
Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...
Read more
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May...
Read more
Telix today announces that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®) positron emission tomography (PET) imaging in clear cell...
Read more
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM...
Read more